Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

NCT03832361 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: IMGN853

Sponsor

Alessandro Santin

Collaborators

[object Object]